Pharmacovigilance Programme of India is Government of India’s flagship drug safety monitoring programme, which collects, collates and analyses drug-related adverse events and send recommendations to CDSCO for taking appropriate regulatory actions. The Ministry of Health and Family Welfare, Government of India recasted PvPI on 15th April, 2011 and shifted the National Coordination Centre from All India Institute of Medical Sciences (AIIMS), New Delhi to IPC, Ghaziabad and is continuing. PvPI plays a crucial role in improving patient safety by promoting a culture of ADR reporting among healthcare professionals and enhancing the benefit-risk profile of medicines. An Adverse Drug Reaction Monitoring Centre (AMC), approved on 20/01/2020, is actively functioning under Al Shifa College of Pharmacy (KIMS Al Shifa Super Specialty Hospital, Perinthalmanna). The centre operates under the leadership of Programme Coordinator Dr. Dilip C., Principal of Al Shifa College of Pharmacy, and Pharmacovigilance Associate Mrs. Shareefa K., who are actively involved in the systematic collection, analysis, and dissemination of ADR safety data. Regular sensitization sessions, workshops, and awareness campaigns are conducted to support healthcare professionals in pharmacovigilance activities. Through its committed participation in PvPI, the AMC has made significant contributions to PvPI by reporting over 5,000 ADRs, and has consistently ranked among the top-performing centres nationally. Based on the 2021 performance report, the centre secured the 13th rank at the national level and 1st position within the state of Kerala. This achievement reflects the institution’s unwavering commitment to pharmacovigilance, patient safety, and the rational use of medicines, positioning it as a leading example in the field.